Western Governors University (WGU) NURS5204 D027 Advanced Pathopharmacological Foundations Practice Exam

The use of glucocorticoids in the treatment of leukemia is well-documented due to their ability to exert direct toxic effects on lymphoid tissues. Glucocorticoids, a class of steroid hormones, are immunosuppressive agents that can induce apoptosis (programmed cell death) in lymphocytes, which is beneficial in the management of hematological malignancies like leukemia. Their mechanism of action involves both anti-inflammatory effects and effects on metabolic pathways that lead to the reduction of lymphoid tissue mass.

Additionally, glucocorticoids are often combined with other therapeutics in leukemia treatment regimens to enhance efficacy, particularly in acute lymphoblastic leukemia (ALL) and some types of non-Hodgkin lymphoma. Their integration into treatment protocols is not solely based on their toxicity but also on their ability to improve the overall response to chemotherapy.

In contrast, the other choices do not share the same application in terms of being directly toxic to lymphoid tissues. Beta-blockers primarily manage cardiovascular conditions and do not have a direct role in treating leukemia. Antibiotics are used to treat infections but do not target cancer cells directly. Antimetabolites, while important in chemotherapy, do not specifically exert their effects through direct toxicity to lymphoid